XERS stock forecast, quote, news & analysis
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States... Show more
Why Xeris Biopharma Holdings (XERS) Stock Is Up +14% in the Last 30 Days
Key Takeaways
- XERS shares advanced roughly 14% over the trailing 30 days, climbing from about $8.95 to near $10.20 amid elevated trading volume.
- The rally was led by reported acquisition interest from Danish pharmaceutical company H. Lundbeck, though Xeris publicly stated it is not for sale.
- Analyst support contributed to momentum, with Leerink Partners raising its price target to $16 from $12 while maintaining an Outperform rating.
- Xeris reinforced its Keveyis franchise by filing patent infringement lawsuits against generic challengers after receiving a new U.S. patent.
- The advance extends a broader uptrend, with the stock up roughly 23% over the trailing quarter on record results and raised 2026 revenue guidance.
- For more detail on valuation and expectations, explore Xeris's Price Targets, Earnings, and Forecast pages.
- Traders can also review automated strategies through Tickeron's Trending AI Robots.
Xeris Biopharma Holdings (XERS) Company Overview and Market Position
Xeris Biopharma Holdings, Inc. is a Chicago-based, commercial-stage biopharmaceutical company focused on endocrine and rare disease therapies. Its three marketed products are Recorlev, a cortisol synthesis inhibitor for endogenous Cushing's syndrome; Gvoke, a ready-to-use liquid glucagon for severe hypoglycemia; and Keveyis, a treatment for primary periodic paralysis.
The company's growth strategy pairs a concentrated commercial portfolio with proprietary formulation technologies, XeriSol and XeriJect, which also support partner programs. Its lead pipeline asset, XP-8121, is a Phase 3-ready, once-weekly subcutaneous injection for hypothyroidism. Investors follow XERS closely because its revenue trajectory depends on continued commercial execution across a relatively narrow product set, making prescription trends, payer dynamics, and pipeline progress central to the investment thesis.
Xeris Biopharma Holdings (XERS) Stock Price Performance: Last 30 Days vs. Quarter
Over the trailing 30 days, XERS moved from a closing price of roughly $8.95 to about $10.20, a gain of approximately 14%. The climb was not linear; the stock spiked sharply in late September after acquisition reports, pulled back in early October, and then reclaimed the $10 to $11 range before easing to near $10.20 on higher-than-average volume.
The quarterly picture is even stronger. Three months earlier, shares traded near $8.32, meaning the stock has gained roughly 23% over that span. This broader advance reflects a steady repricing of the company's fundamentals, driven by record quarterly revenue, raised full-year guidance, and a simplified balance sheet following the retirement of convertible notes. The stock's 52-week range of approximately $5.25 to $11.42 underscores how far shares have traveled from their prior lows.
What Drove XERS Stock Price in the Last 30 Days
The most significant catalyst was a late-September report that H. Lundbeck, a Danish pharmaceutical company, was exploring a potential acquisition of Xeris. Shares surged roughly 6% on the news even as Xeris stated it was not for sale and remained focused on its mission. Acquisition interest of this kind often triggers a repricing as investors weigh the strategic value of a company's commercial portfolio and pipeline.
Analyst activity reinforced the move. In early September, Leerink Partners analyst Roanna Ruiz raised the firm's price target to $16 from $12 while reiterating an Outperform rating, signaling confidence in the company's execution. Separately, in mid-October, Xeris filed patent infringement lawsuits in the District of New Jersey against multiple generic manufacturers over a newly granted U.S. patent related to Keveyis, a step aimed at protecting a key revenue stream.
Offsetting factors included a series of routine insider sales by executives during September and October, which are common but can temper sentiment. Broader valuation debates also surfaced, with some third-party models flagging the stock as trading at a premium to historical multiples while revenue growth remains the primary driver of value.
What Drove XERS Stock Performance Over the Last Quarter
The quarterly gain reflects improving fundamentals rather than a single headline. Xeris reported a record second quarter, with Recorlev growing 81% year over year, and raised the lower end of its 2026 total revenue guidance to $385 million to $390 million. Management also completed the retirement of its 8.00% convertible senior notes due 2028, simplifying the capital structure and reducing potential dilution.
Intellectual property progress added support, including a U.S. Patent and Trademark Office notice of allowance for a Keveyis-related patent that could extend protection toward 2039. Governance changes accompanied the momentum, with CEO John Shannon becoming Chair of the Board and the board expanding with new appointments. Together, these developments shifted the narrative from balance-sheet management toward commercial execution and pipeline advancement.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of AI-powered trading bots. While Tickeron offers hundreds of bots trading thousands of tickers, only the top-performing and most relevant strategies appear in this section. Each bot differs in its trading style, timeframe, and performance metrics, allowing users to evaluate approaches that range from short-term momentum to longer-horizon trend following. The page is designed to help traders explore automated strategies and identify tools that align with their own objectives and risk tolerance. Those interested in systematic trading can review the featured bots to see how AI-driven signals are applied across markets.
XERS Stock Forecast Drivers: What Investors Should Watch Next
The next major checkpoint is Xeris's third-quarter 2026 earnings report, scheduled for November 5, 2026. Investors will focus on Recorlev's prescription and new-patient trends, any recovery in Gvoke following Medicare-related pressure earlier in the year, and whether Keveyis maintains its growth trajectory.
Beyond earnings, key watch items include further commentary on the Lundbeck acquisition interest, the outcome of the newly filed Keveyis patent litigation, and progress updates on XP-8121's Phase 3 program and commercialization timeline. Macroeconomic and policy factors, including payer dynamics and potential healthcare regulation changes, could also influence demand across the company's products. As always, product concentration remains a central risk, since a meaningful portion of revenue is tied to a small number of therapies.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Momentum Indicator for XERS turns positive, indicating new upward trend
XERS saw its Momentum Indicator move above the 0 level on November 05, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 83 similar instances where the indicator turned positive. In 72 of the 83 cases, the stock moved higher in the following days. The odds of a move higher are at 87%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for XERS just turned positive on November 05, 2026. Looking at past instances where XERS's MACD turned positive, the stock continued to rise in 34 of 42 cases over the following month. The odds of a continued upward trend are 81%.
Following a +21.25% 3-day Advance, the price is estimated to grow further. Considering data from situations where XERS advanced for three days, in 223 of 259 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
The Aroon Indicator entered an Uptrend today. In 191 of 232 cases where XERS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 82%.
Bearish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where XERS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 77%.
XERS broke above its upper Bollinger Band on November 05, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 1 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: XERS's P/B Ratio (-284.700) is very low in comparison to the industry average of (6.379). XERS has a moderately low P/E Ratio (-152.000) as compared to the industry average of (0.548). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.062) among similar stocks. P/S Ratio (4.196) is also within normal values, averaging (183.387).
The Tickeron Profit vs. Risk Rating rating for this company is 7 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. XERS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 99 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of ready-to-use, liquid-stable injectables
Industry PharmaceuticalsGeneric